

Termination of the Proposed Sale of the Myrian® Business to EDL

Montpellier, France, August 3rd, 2026, 5:45 PM. [Intrasense \(FR0011179886 - ALINS\)](#), a French expert in AI-enhanced medical imaging solutions facilitating diagnosis, decision-making and therapeutic follow-up, announces the termination of the proposed sale of the technological assets, intellectual property, customer and partner contracts, and the teams dedicated to the Myrian business to EDL.

The discussions announced on July 1, 2026¹, did not result in an agreement, and the transaction relating to the sale of the Myrian® business could not be finalized between the parties. As a result, the proposed transaction will not proceed under the terms previously disclosed.

Intrasense remains committed to the implementation of its cost-saving plan, including a reduction in headcount and external expenses, while continuing to pursue financing solutions to support its growth.

Next financial announcement:

2026 Half-Year Results: September 28 (after market close)

About Intrasense

A French expert in medical imaging since 2004 and a digital subsidiary of the Guerbet Group since 2023, Intrasense develops medical imaging software solutions that are now firmly focused on artificial intelligence. Intrasense's product portfolio includes:

- Myrian®, an advanced visualization platform equipped with state-of-the-art clinical tools that simplifies the interpretation of all types of images.
- DUOnco™: a suite of AI algorithms specialized in oncology, including those for the detection of pancreatic lesions and focal liver lesions, as well as the world's first CE-certified AI dedicated to bone lesions.
- Liflow® (still in the controlled-release phase), a solution designed for the longitudinal monitoring of oncology patients.

By combining clinical expertise and operational excellence, Intrasense provides healthcare professionals with tools of high medical value that facilitate the analysis, diagnosis, and care of patients.

For more information, visit: www.intrasense.fr

Contact

Intrasense

Communication officer

Mathilda Vigne-Salade

Tél. : +334 67 13 01 30

investisseurs@intrasense.fr

Seitosei-Actifin

Analyst & Investor Relations

Foucauld Charavay

Tél. : +336 37 83 33 19

intrasense@seitosei-actifin.com

Press Relations

Isabelle Dray

Tél. : +331 56 88 11 29

Isabelle.dray@seitosei-actifin.com

¹ Press Release on 1 July 2026 - Proposed Disposal of Intrasense's Myrian® Business to EDL and Acceleration of Intrasense's Transformation into a Pure-Player Artificial Intelligence Company Dedicated to Oncology